Trial Profile
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Aug 2013 Results published in the European Respiratory Journal.
- 20 May 2012 Primary endpoint "Mean Change in Exercise Endurance Time (EET) From Baseline to Week Four (end of the treatment period)' has not been met, according to results reported at the 108th International Conference of the American Thoracic Society.
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.